ReviewPituitary2020
Suprasellar pituitary adenomas: a 10-year experience in a single tertiary medical center and a literature review.
Review in Pituitary, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 22 citations in OpenAlex.
- Pituitary tuberculosis in the pediatric population: a systematic review and case report.Pituitary · 2025Pooled it
- Clinical and radiological presentation of parasellar ectopic pituitary adenomas: case series and systematic review of the literature.Journal of endocrinological investigation · 2022Pooled it
- Growth hormone-releasing hormone, growth hormone, and neuroendocrine tumors.Journal of clinical & translational endocrinology · 2026Review
- Endoscopic endonasal resection of ectopic suprasellar pituitary neuroendocrine tumors: comparison of intra-stalk and extra-stalk tumors. Illustrative cases.Journal of neurosurgery. Case lessons · 2026Article
- Prognostic factors in the surgical treatment of non-functioning pituitary adenomas: a retrospective cohort study.Archives of endocrinology and metabolism · 2026Article
- Effectiveness of a Modified Transsellar Approach with Planum Sphenoidale Removal for Pituitary Neuroendocrine Tumors with Anterosuperior Extension.Journal of clinical medicine · 2026Article
- Endoscopic endonasal resection of neurohypophyseal granular cell tumor: a case report and review of 88 published cases.Frontiers in endocrinology · 2026Review
- Case Report: Pediatric ACTH-secreting pituitary adenoma presenting with hypertension and anuria.Frontiers in endocrinology · 2026Article
- Acidophil stem cell-like pituitary neuroendocrine tumors with heterogeneous PIT1/SF1 or LH lineage-marker expression: a clinicopathological study of three cases.Frontiers in endocrinology · 2026Article
- Organization and resource utilization of specialized neurosurgical care for chiasmatic-sellar tumors in a metropolitan health system: a hospital-based study from Kazakhstan.Frontiers in health services · 2026Article
- Predicting resection success in giant pituitary adenomas: morphologic determinants and a preoperative multivariate model.Frontiers in endocrinology · 2026Article
- Article
- Endoscopic endonasal surgery for suprasellar ectopic pituitary neuroendocrine tumors featuring apoplexy and a preoperative differential diagnosis: illustrative cases.Journal of neurosurgery. Case lessons · 2025Article
- Risk factors associated with acute pancreatitis in diabetic ketoacidosis patients: a 11-year experience in a single tertiary medical center and comprehensive literature review.Frontiers in medicine · 2025Article
- Predictors of delayed hyponatremia after endoscopic transsphenoidal surgery for non-functioning pituitary adenomas.Frontiers in endocrinology · 2025Article
- Pituitary macroadenomas in childhood and adolescence: a clinical analysis of 7 patients.Clinical diabetes and endocrinology · 2023Article
- Endoscopic Endonasal Transplanum-Transtuberculum Approach for Pituitary Adenomas/PitNET: 25 Years of Experience.Brain sciences · 2023Article
- High-Grade Ectopic Pituitary Adenoma within the Cerebellopontine Angle: A Case Report.Journal of neurological surgery reports · 2023Article
- Decision-Making and Management in a Patient With Coexistent Colloid Cyst and Pituitary Macroadenoma: A Case Report.Cureus · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
backgroundSuprasellar pituitary adenomas (SPAs) are a special type of pituitary adenoma. Although dozens of SPA cases have been reported, the exact definition and the characteristics of SPA have not been exhaustively discussed before.
methodsIn a retrospective electronic medical records review, 13 patients with SPA were identified in our hospital between January 2010 and December 2019. A literature review was performed by searching the online database PubMed, and 39 cases conformed to the criteria based on the previous literature. Data regarding clinical symptoms, imaging manifestations, surgical information and follow-ups were analyzed.
resultsThe mean age at diagnosis of 52 patients with SPA was 36.73 years, and most of the patients were female (61.5%). The most common hormone-secreting subtypes of SPA were nonfunctioning (36.5%) and ACTH-secreting (34.6%) SPA. Macroadenomas (68.9%) were more common than microadenomas (31.1%). The origins of the SPAs included the intrasellar pituitary gland (type I), the subdiaphragmatic (type IIa) and supradiaphragmatic (type IIb) part of the pituitary stalk, and the suprasellar peri-infundibular region (type III). The most common anatomic subtype of SPA was type III, and type IIb was also common. The most common presentations of SPA were visual symptoms, especially for type III SPA. In addition, 64.7% and 73.1% of type IIb and III SPAs, respectively, were suspected to be of suprasellar origin based on presurgical imaging examination. Patients with tumors of suspected suprasellar origin were more likely to receive transcranial surgery (TCS) initially than those with tumors of suspected intrasellar origin (70.6% vs. 22.2%, p = 0.0013). The intact rate for the pituitary stalk after surgery for type II SPA was lower than that for type I and III SPA (52.6% vs. 92.6%, p = 0.0036). More patients with type II SPA experienced postoperative central diabetes insipidus (CDI) than those with type I and III SPA (57.9% vs. 11.1%, p = 0.0011). There was no significant difference in the incidence of postoperative CDI between transsphenoidal surgery (TSS) and TCS (p = 0.1304). Nine patients in our hospital received extended endoscopic TSS; only one experienced tumor recurrence, and no severe complications occurred after surgery.
conclusionsSPAs could be defined as pituitary adenomas completely or partially located in the suprasellar region. There were both similarities and differences among the different anatomic subtypes of SPA. For patients who were suspected of having SPAs, visual field tests, pituitary hormone evaluation and MRI were necessary. Because imaging examination is not a reliable method, surgery is the only way to confirm the tumor origin. Extended endoscopic TSS might be a safe and efficient approach to remove these tumors, but more studies are needed to verify this conclusion. For type II SPA, the pituitary stalk should be carefully protected during surgery, and postoperative CDI should be monitored.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.